Program
Torsemide
Also written as “Torasemide tablet 10 mg”, “torasemide” and “torsemide”.
Its studies are mostly in Heart Failure · Edema · Body Weight Changes · Hypertension · Diabetes Mellitus, Type 2, led by 5 companies.
Drug pageTorsemide: every studyMany companies study it; this page follows only the 11 they lead. All 23 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sarfez Pharmaceuticalsits history only | 40 open or running | phase 4since Nov 24, 2024 | Apr 17, 2018 | none ahead |
| Ferrer Internacionalits history only | 20 open or running | phase 4since Jun 6, 2006 | Jun 6, 2006 | none ahead |
| Hikma Pharmaceuticalsits history only | 20 open or running | no phasesince Jan 15, 2008 | Jan 15, 2008 | none ahead |
| Par Healthits history only | 20 open or running | phase 1since Apr 1, 2008 | Apr 1, 2008 | none ahead |
| Menarini Groupits history only | 11 open or running | phase 1since Sep 10, 2025 | Sep 10, 2025 | none ahead |
Also a collaborator on its studies: Anapharm.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 6, 2006First study: phase 4 study in HypertensionNew to Ferrer InternacionalFerrer Internacional · NCT00334386 · 388 enrolled
- Dec 11, 2006Phase 4 study in Heart FailureFerrer Internacional · NCT00409942 · 142 enrolled · Spain
- Jan 15, 2008Hikma Pharmaceuticals’ first studies: 2 no phase studies in EdemaNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT00602615, NCT00602303
- Apr 1, 2008Par Health’s first studies: 2 phase 1 studiesNew to Par HealthPar Health · NCT00654043, NCT00653549
- Apr 17, 2018Sarfez Pharmaceuticals’ first study: phase 1 study in Body Weight ChangesNew to Sarfez PharmaceuticalsSarfez Pharmaceuticals · NCT03509545 · 20 enrolled · India
- Nov 24, 2024Phase 4 study in Heart FailureSarfez Pharmaceuticals · NCT06708611 · United States
- Jun 3, 20252 phase 3 studiesSarfez Pharmaceuticals · NCT07015671, NCT07046975
- Sep 10, 2025Menarini Group’s first study: phase 1 study in Healthy Adult Male and Female VolunteersNew to Menarini GroupMenarini Group · NCT07201584 · 26 planned · Kazakhstan
TargetBeta
“Sodium-(potassium)-chloride cotransporter 2 inhibitor”ChEMBL 37, by rule
Other programs on SLC12A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Furosemiderule | Boehringer Ingelheim | phase 4 | 27 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07201584Healthy Adult Male and Female Volunteers · Kazakhstan | 1 | Recruiting | Menarini Group | Dec 30, 2025 | 26 |
| NCT07046975Bioavailability Heathy Volunteers · United States | 3 | Completed | Sarfez Pharmaceuticals | Feb 28, 2026 | 24 |
| NCT07015671Bioequivalence Study in Healthy Subjects · United States | 3 | Completed | Sarfez Pharmaceuticals | Dec 30, 2025 | 24 |
| NCT06708611Heart Failure · United States | 4 | Withdrawn | Sarfez Pharmaceuticals | Mar 25, 2025 | 0 |
| NCT03509545Body Weight Changes · India | 1 | Terminated | Sarfez Pharmaceuticals | Jun 30, 2022 | 20 |
| NCT00654043Lecithin Cholesterol Acyltransferase Deficiency | 1 | Completed | Par Health | May 2001 | 24 |
| NCT00653549Fasting | 1 | Completed | Par Health | May 2001 | 26 |
| NCT00602615Edema · United States | – | Completed | Hikma Pharmaceuticals | Sep 2003 | 28 |
| NCT00602303Edema · United States | – | Completed | Hikma Pharmaceuticals | Sep 2003 | 28 |
| NCT00409942Heart Failure · Spain | 4 | Completed | Ferrer Internacional | Jun 2009 | 142 |
| NCT00334386Hypertension | 4 | Completed | Ferrer Internacional | 388 |
How it is read
Names in the registry
- “Torsemide”, 4 entries
- “Torasemide tablet 10 mg”, 2 entries
- “torasemide”, 2 entries
- “torsemide”, 1 entry
- “CHF Patients: ER Torsemide 40 mg”, 1 entry
Conditions, from the studies’ own filings
- Heart Failure, 2 studies
- Edema, 2 studies
- Body Weight Changes, 1 study
- Hypertension, 1 study
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.